Summit Therapeutics (NASDAQ:SMMT – Get Free Report) had its price target cut by stock analysts at Citigroup from $43.00 to $42.00 in a research report issued on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Citigroup‘s price objective suggests a potential upside of 252.53% from the stock’s current price.
A number of other analysts have also issued reports on SMMT. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Summit Therapeutics in a report on Monday, October 5th. Jefferies Financial Group restated a “buy” rating on shares of Summit Therapeutics in a research note on Sunday. Barclays cut their price objective on Summit Therapeutics from $20.00 to $18.00 and set an “equal weight” rating for the company in a research report on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Summit Therapeutics in a research note on Thursday, October 15th. Finally, UBS Group restated a “neutral” rating on shares of Summit Therapeutics in a research report on Wednesday, September 23rd. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Summit Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $28.38.
Check Out Our Latest Report on Summit Therapeutics
Summit Therapeutics Stock Down 15.8%
SMMT stock traded down $2.24 during trading hours on Monday, hitting $11.91. The company’s stock had a trading volume of 17,177,827 shares, compared to its average volume of 4,702,207. Summit Therapeutics has a 12 month low of $11.69 and a 12 month high of $29.23. The stock has a 50 day moving average price of $16.41 and a two-hundred day moving average price of $16.14. The company has a market capitalization of $9.53 billion, a PE ratio of -11.07 and a beta of -1.49.
Hedge Funds Weigh In On Summit Therapeutics
Hedge funds have recently modified their holdings of the stock. Cetera Investment Advisers raised its position in Summit Therapeutics by 54.3% during the third quarter. Cetera Investment Advisers now owns 44,592 shares of the company’s stock worth $754,000 after acquiring an additional 15,691 shares in the last quarter. State Board of Administration of Florida Retirement System grew its position in shares of Summit Therapeutics by 1.1% in the third quarter. State Board of Administration of Florida Retirement System now owns 95,254 shares of the company’s stock valued at $1,611,000 after purchasing an additional 1,025 shares during the last quarter. Xcelsior Advisor Partners LLC lifted its holdings in shares of Summit Therapeutics by 199.7% during the third quarter. Xcelsior Advisor Partners LLC now owns 53,874 shares of the company’s stock worth $911,000 after buying an additional 35,899 shares in the last quarter. Ieq Capital LLC bought a new stake in Summit Therapeutics in the 3rd quarter valued at about $1,179,000. Finally, Z3 Capital Partners LLC acquired a new stake in Summit Therapeutics during the third quarter worth approximately $618,000. Institutional investors own 4.61% of the company’s stock.
Trending Headlines about Summit Therapeutics
These are some of the SMMT headlines that stood out recently:
- Neutral Sentiment: Options trading was unusually active: traders acquired 49,767 call options, about 424% above the average daily volume. That signals heightened interest, but does not by itself establish a bullish outlook. 2 Cancer-Drug Developers Seeing Unusual Options Volume
- Negative Sentiment: The FDA issued a Complete Response Letter for ivonescimab with platinum-containing chemotherapy in previously treated, locally advanced or metastatic non-small cell lung cancer. The drug cannot be approved on the current application, delaying its potential U.S. launch; the supplied reports do not specify the FDA’s reasons. Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application
- Negative Sentiment: Barclays cut its price target from $20 to $18 while maintaining an “equal weight” rating, adding to the cautious tone around the stock. Barclays Stock Recommendations
Summit Therapeutics Company Profile
Summit Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its lead candidate is ivonescimab, a bispecific antibody designed to target both PD-1 and VEGF, two pathways involved in tumor growth and the immune response. The company is evaluating the treatment in clinical trials for multiple types of cancer. Summit licensed rights to develop and commercialize ivonescimab from China-based Akeso in 2022. Summit’s licensed territory covers markets outside China, including the United States, Canada, Europe and Japan.
Further Reading
- Five stocks we like better than Summit Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
